Skip to main navigation
MBX Bio Logo
  • Our Science
    • How PEPs™ Work
    • Development Programs
  • Platform
    • Our Pipeline
      • Canvuparatide
      • MBX 4219
      • MBX 5765
      • MBX 6180
  • Patients
    • Current Clinical Trials
    • Patient Stories
    • Resources & Advocacy
  • About Us
    • Mission
    • Core Values
    • Leadership Team
    • Board of Directors
    • Scientific Advisory Board
  • Investors
    • News & Events
      • News Releases
      • Events
      • Presentations
    • Corporate Governance
      • Governance Overview
      • Board of Directors
      • Leadership Team
      • Committee Composition
    • Financial Information
      • SEC Filings
    • Stock Information
      • Stock Quote & Chart
      • Analyst Coverage
    • Shareholder Services
      • Investor FAQs
      • Email Alerts
      • RSS Feeds
      • Contact IR
  • Careers
  • Contact Us

News Releases

August 6, 2026
MBX Biosciences Reports Second Quarter 2026 Financial Results and Corporate Highlights
July 13, 2026
MBX Biosciences Announces Executive Leadership Transition to Support the Company’s Next Phase of Growth
June 12, 2026
MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism
June 1, 2026
MBX Biosciences to Host Virtual Investor Event to Discuss Once-Weekly Canvuparatide Presentations at ENDO 2026
May 26, 2026
MBX Biosciences to Present at the Jefferies 2026 Global Healthcare Conference in New York City
May 11, 2026
MBX Biosciences Provides Obesity Portfolio Update Including Initial Phase 1 Data for MBX 4291 Supporting Potential for Once-Monthly Dosing
May 7, 2026
MBX Biosciences Reports First Quarter 2026 Financial Results and Corporate Highlights
May 7, 2026
MBX Biosciences Announces Appointment of Mark Soued as Chief Commercial Officer and Inducement Grant Award
April 23, 2026
MBX Biosciences to Host In-Person and Virtual Obesity Day on May 11, 2026 to Discuss Expanding Obesity Portfolio
April 3, 2026
MBX Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
  • Current page 1
  • Page 2
  • Next page ›
  • Last page »
Displaying 1 - 10 of 17
MBX Bio Logo

MBX Biosciences is a biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies based on its proprietary PEP™ platform, for the treatment of endocrine and metabolic disorders. The Company is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities.

FOLLOW US

Facebook Logo Twitter Logo LinkedIn Logo

©2026 MBX Bio. All Rights Reserved.

  • Contact Us
  • Privacy Policy
  • Terms of Use

Website design by Mentus

©2026 MBX Bio. All Rights Reserved.

Website design by Mentus